Abstract
Reverse transcriptase (RT), an essential enzyme for HIV-1 (human immunodeficiency virus type-1) life cycle, is a key target in drug discovery efforts against HIV-1 infection. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are very specific to HIV-1 RT and have relatively less toxicity than the nucleoside reverse transcriptase inhibitors (NRTIs). However, the rapid emergence of drug-resistant viral strains has limited the therapeutic efficacy of these inhibitors. In this review, recent advances in computer-aided drug design (CADD) for design of new compounds against HIV-1 RT based on ligand-based drug design (LBDD) using 2D-and 3D-QSAR approaches, structure-based drug design (SBDD) with the combination of molecular docking, virtual screening and de novo drug design, molecular simulations and particular interaction calculated from quantum chemical calculations are discussed. Their successful applications are also highlighted.
Keywords: Human immunodeficiency virus type-1, computer-aided drug design, non-nucleoside reverse transcriptase inhibitors, structure-based drug design, ligand-based drug design, quantum chemical calculations, molecular simulation
Current Computer-Aided Drug Design
Title: Recent Advances in NNRTI Design: Computer-Aided Molecular Design Approaches
Volume: 5 Issue: 3
Author(s): Pornpan Pungpo, Auradee Punkvang, Patchreenart Saparpakorn, Peter Wolschann and Supa Hannongbua
Affiliation:
Keywords: Human immunodeficiency virus type-1, computer-aided drug design, non-nucleoside reverse transcriptase inhibitors, structure-based drug design, ligand-based drug design, quantum chemical calculations, molecular simulation
Abstract: Reverse transcriptase (RT), an essential enzyme for HIV-1 (human immunodeficiency virus type-1) life cycle, is a key target in drug discovery efforts against HIV-1 infection. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are very specific to HIV-1 RT and have relatively less toxicity than the nucleoside reverse transcriptase inhibitors (NRTIs). However, the rapid emergence of drug-resistant viral strains has limited the therapeutic efficacy of these inhibitors. In this review, recent advances in computer-aided drug design (CADD) for design of new compounds against HIV-1 RT based on ligand-based drug design (LBDD) using 2D-and 3D-QSAR approaches, structure-based drug design (SBDD) with the combination of molecular docking, virtual screening and de novo drug design, molecular simulations and particular interaction calculated from quantum chemical calculations are discussed. Their successful applications are also highlighted.
Export Options
About this article
Cite this article as:
Pungpo Pornpan, Punkvang Auradee, Saparpakorn Patchreenart, Wolschann Peter and Hannongbua Supa, Recent Advances in NNRTI Design: Computer-Aided Molecular Design Approaches, Current Computer-Aided Drug Design 2009; 5 (3) . https://dx.doi.org/10.2174/157340909789054685
DOI https://dx.doi.org/10.2174/157340909789054685 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Immunomodulatory Therapy Associated to Anti-Parasite Drugs as a Way to Prevent Severe Forms of Malaria
Current Clinical Pharmacology Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Crotamine, a Small Basic Polypeptide Myotoxin from Rattlesnake Venom with Cell-Penetrating Properties
Current Pharmaceutical Design Endothelial Cells Facilitate Cell-Based Cardiac Repair: Progress and Challenge
Current Stem Cell Research & Therapy Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation
Current Drug Targets Meet Our Editorial Board Member
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adenine-N3 in the DNA Minor Groove - An Emerging Target for Platinum Containing Anticancer Pharmacophores
Anti-Cancer Agents in Medicinal Chemistry Development of Novel Rhodacyanine-Based Heat Shock Protein 70 Inhibitors
Current Medicinal Chemistry Recent Applications of Bioinformatics in Target Identification and Drug Discovery for Alzheimer’s Disease
Current Topics in Medicinal Chemistry The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Plant-Derived Natural Compounds for the Treatment of Amyotrophic Lateral Sclerosis: An Update
Current Neuropharmacology Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs
Current Bioactive Compounds Defense-related Proteins from Chelidonium majus L. as Important Components of its Latex
Current Protein & Peptide Science Strategies to Improve Insulin Delivery through Oral Route: A Review
Current Drug Delivery The Genomics of Colorectal Cancer: State of the Art
Current Genomics Applications of Lipid-based Nanocarriers for Parenteral Drug Delivery
Current Medicinal Chemistry De Novo Design of High Potent DPP-IV Inhibitors Based on the Scaffold of Cyanopyrrolidine
Letters in Drug Design & Discovery Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening